Navigation Links
Ariosa Diagnostics Announces Publication of Study on Influential Factors Affecting Fetal DNA Concentration in Blood of Pregnant Women
Date:5/23/2012

SAN JOSE, Calif., May 23, 2012 /PRNewswire/ -- Ariosa Diagnostics, a molecular diagnostics company, announced today the publication of a study that provides more information on the factors which may influence the amount of fetal DNA found in maternal blood. The study was led by Professor Kypros Nicolaides, MD, of Harris Birthright Research Centre for Fetal Medicine at King's College Hospital in the United Kingdom.

(Logo: http://photos.prnewswire.com/prnh/20120326/NY75864LOGO )

The study demonstrated that fetal DNA amounts did not differ significantly between pregnant women who have Trisomy 21 fetuses (associated with Down syndrome) and those who have euploid fetuses (no trisomy). Maternal weight and serum screening markers were found to correlate with fetal DNA amounts suggesting that placental size relative to the mother is the major factor influencing fetal DNA concentration in maternal blood. The study, which will be published in a future print edition of Fetal Diagnosis & Therapy, is available now online at http://content.karger.com/produktedb/produkte.asp?DOI=10.1159/000337373.

"The ability to detect Trisomy 21 with cell-free DNA is dependent upon assay precision and fetal fraction in the sample rather than upon the prevalence of disease in the study population," stated Professor Nicolaides. "While further studies are warranted, our results suggest that cell free DNA testing may be applicable in both high and low risk pregnancies."

"We are committed to advancing science and research in the field of non-invasive prenatal testing," said Ken Song, chief executive officer at Ariosa Diagnostics. "It is important that clinical data and scientific principles take center stage as non-invasive tests, such as the Harmony™ Prenatal Test, are used by healthcare providers to manage pregnant women. This additional research into the presence of fetal DNA in maternal blood will help us to better identify which patients may be appropriate for prenatal testing."

Ariosa Diagnostics developed the Harmony Prenatal Test, which is currently available in selected US locations and will be broadly available in June. The Harmony Prenatal Test is performed using a simple maternal blood draw and detects fetal trisomy via analysis of cell-free DNA in maternal blood.

About Ariosa Diagnostics

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to providing safe, highly accurate and affordable prenatal tests for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. Ariosa's simple blood test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com.


'/>"/>
SOURCE Ariosa Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ariosa Diagnostics Announces Nationwide Launch of the Harmony™ Prenatal Test Through LabCorp
2. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
3. Quest Diagnostics Announces C9orf72 Genetic Test for ALS (Lou Gehrigs Disease)
4. Nanoscale magnetic media diagnostics by rippling spin waves
5. Aviir Diagnostics Laboratory in Collaboration with Cause;ology Sponsors "Storyland," a Red Carpet Charity Extravaganza in Hollywood
6. Berg Diagnostics Receives CLIA Certification and Launches Novel Vitamin D Assay
7. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
8. The butterfly effect in nanotech medical diagnostics
9. Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
10. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
11. ZyGEM to Provide its Unique DNA and RNA Extraction Technology to Middle East Biomedical Innovator Saudi Diagnostics Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... ... delivery of product vigilance software to leading biopharmaceutical and medical device manufacturers and ... is a fully 21 CFR Part 11-compliant email client designed to provide product ...
(Date:1/19/2017)... AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), ... and a majority-owned subsidiary of Intrexon Corporation (NYSE: ... listing of its common shares on the NASDAQ Stock ... "AquaBounty,s listing on NASDAQ represents an important milestone ... the U.S. markets as we advance plans for commercial ...
(Date:1/19/2017)... , ... January 19, 2017 , ... FireflySci Inc. is ... rate. The tremendous growth is accounted to two main factors. The first ... the expanding network of vendors supplying FireflySci products all around the world. , 2016 ...
(Date:1/19/2017)...  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a ... operable and inoperable solid tumor cancers, announced today that ... NW Bio, will present at the Phacilitate Immunotherapy World ... Regency Hotel in Miami, Florida . ... "New Therapeutic Approaches – Expanding the Reach of Cancer ...
Breaking Biology Technology:
(Date:1/18/2017)... MINNETONKA, Minn. , Jan. 18, 2017 /PRNewswire/ ... eClinical technology company that supports the entire spectrum ... 2016 has been another record-breaking year for the ... and market interest in MedNet,s eClinical products and ... to the tremendous marketplace success of ...
(Date:1/12/2017)... 2017  New research undertaken by Fit Small Business ... 1,000 participants were simply asked which office technology had they ... consider standard issue.  Insights on what will be ... from futurists and industry leaders including Penelope Trunk , ... Some of these findings included; ...
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol Inc. ... Group, Inc., has been named to the elite "Forbes 30 Under ... one of 600 people in 20 fields nationwide to be recognized ... the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers University. ...
Breaking Biology News(10 mins):